Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABX203 therapeutic Hepatitis B vaccine treatment arm · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm | EXPERIMENTAL | ABX203 therapeutic vaccine in addition to NUCs background therapy |
| Group 2 - Control arm | NO_INTERVENTION | NUCs background therapy only |
| Name | Type | Description |
|---|---|---|
| ABX203 therapeutic Hepatitis B vaccine treatment arm | DRUG | - |
Inclusion Criteria: * Male or female subject between 18 and 65 years of age at the time of randomization. * Must be HBeAg negative and anti-HBe Abs positive for at least 1 year prior to screening and at screening. * Has HBV DNA \< 40 IU/mL for at least 1 year prior to screening and at screening * H...
ABX203 is an investigational therapeutic vaccine being developed for the treatment of chronic Hepatitis B. It is designed for use in patients with chronic Hepatitis B, specifically those who are HBeAg negative. It is administered as a treatment for people already infected with the hepatitis B virus, rather than as a preventive vaccine.
ABX203 is being developed by Abivax SA, a biopharmaceutical company whose shares trade under the ticker ABVX. Abivax is the sponsor of the clinical program evaluating ABX203 in chronic Hepatitis B.
ABX203 is in Phase 2 clinical development. The Phase 2 trial evaluating ABX203 in chronic Hepatitis B has been completed. ABX203 is an investigational therapeutic vaccine and has not been approved by the FDA for any indication.
ABX203 has been studied in one Phase 2 clinical trial, NCT02249988, titled Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B. The trial enrolled 261 patients, was randomized and no-treatment controlled, and was conducted in Australia and New Zealand. It is now completed.
The ABX203 therapeutic Hepatitis B vaccine treatment arm refers to the group of patients in the Phase 2 trial NCT02249988 who received ABX203. This trial evaluated ABX203 in HBeAg negative patients with chronic Hepatitis B, enrolled 261 participants, and used a randomized, no-treatment controlled design.